Doomsdays for Valeant, Biogen and biotech VC

Fierce editors discuss a rough day for Valeant Pharmaceuticals and Biogen, plus the changing in winds in biotech venture capital.

Related Episodes

Continue listening to more episodes from FierceBiotech Radio.

May 15, 2018 - 15:46

FierceBiotech chats with a pair of lawyers about how drug pricing is unique in the U.S. and how the bioph...

Mar 13, 2018 - 21:26

Fierce editors discuss the 2018 FierceMadness drug name tournament, its origins, and our favorites headin...

Oct 31, 2017 - 09:46

FierceBiotech Radio rose from the grave for this special Halloween episode where we sat down with some of...

Mar 18, 2016 - 28:41

Fierce editors discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decis...

Feb 26, 2016 - 41:26

Fierce editors discuss the confirmation of Robert Califf as the next FDA commissioner, Sanofi's efforts t...

Feb 18, 2016 - 39:23

Fierce editors discuss the rise of TV ads for specialty drugs, signs of life in the biotech IPO scene, an...

Feb 11, 2016 - 40:30

Fierce editors discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, a...

Feb 4, 2016 - 36:41

Fierce editors discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the l...